Carmen García‐Hernández

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Haifa Kathrin Al‐Ali, Martin Grießhammer, Lynda Foltz et al. · British Journal of Haematology · 2020 · 113 citations · Full text

Medicine, Hematology, Pharmacology +14

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Valentín García‐Gutiérrez, Alejandro Luna, Juan Manuel Alonso‐Domínguez et al. · Blood Cancer Journal · 2021 · 44 citations · Full text

Medicine, Hematology, Oncology +8

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

Alberto Álvarez‐Larrán, Marta Garrote, Francisca Ferrer‐Marín et al. · Cancer · 2022 · 32 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Adrián Mosquera-Orgueira, Manuel Pérez‐Encinas, Alberto Hernández‐Sánchez et al. · HemaSphere · 2022 · 30 citations · Full text

Computing, Biostatistics, Clinical Sciences +17

Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

Fabián Tarín, Francisco López, Carmen García‐Hernández et al. · Acta Haematologica · 2018 · 23 citations

Medicine, Hematology, Pathology +16